Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients

Mudd, 1995, Disorders of transsulfuration,, 1279

Duell, 1997, Homocyst(e)ine: An important risk factor for atherosclerotic vascular disease, Curr Opin Lipidol, 8, 28, 10.1097/00041433-199702000-00007

D’Angelo, 1997, Homocysteine and thrombotic disease, Blood, 90, 1, 10.1182/blood.V90.1.1

Graham, 1997, Plasma homocysteine as a risk factor for vascular disease: The European concerted action project, JAMA, 277, 1775, 10.1001/jama.1997.03540460039030

Motulsky, 1996, Nutritional ecogenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid, Am J Hum Genet, 58, 17

Bostom, 1995, Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study, Atherosclerosis, 114, 93, 10.1016/0021-9150(94)05470-4

Bostom, 1997, Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes, Kidney Int, 52, 10, 10.1038/ki.1997.298

Wilcken, 1979, Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide, Eur J Clin Invest, 9, 301, 10.1111/j.1365-2362.1979.tb00888.x

Wilcken, 1980, Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis, Clin Sci, 58, 427, 10.1042/cs0580427

Kang, 1983, Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis, Clin Sci, 65, 335, 10.1042/cs0650335

Smolin, 1987, Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis, Am J Clin Nutr, 45, 737, 10.1093/ajcn/45.4.737

Soria, 1990, Concentrations of total homocysteine in plasma in chronic renal failure, Clin Chem, 36, 2137, 10.1093/clinchem/36.12.2137

Hultberg, 1993, Plasma homocysteine in renal failure, Clin Nephrol, 40, 230

Chauveau, 1993, Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients, Kidney Int, 43, S72

Bostom, 1995, Net uptake of plasma homocysteine by the rat kidney in vivo, Atherosclerosis, 116, 59, 10.1016/0021-9150(95)05522-X

Foreman, 1982, Homocystine uptake in isolated rat renal cortical tubules, Metabolism, 31, 613, 10.1016/0026-0495(82)90101-9

McKeever, 1991, Betaine-homocysteine methyltransferase: Organ distribution in man, pig and rat and subcellular distribution in the rat, Clin Sci, 81, 551, 10.1042/cs0810551

Gaull, 1973, Development of methyltransferase activities of human fetal tissues, Pediatr Res, 7, 527, 10.1203/00006450-197305000-00006

Baumgartner, 1985, Comparison of folic acid coenzyme distribution patterns in patients with methylenetetrahydrofolate reductase and methionine synthetase deficiencies, Pediatr Res, 91, 1288, 10.1203/00006450-198512000-00017

Bostom, 1996, Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients, Atherosclerosis, 123, 193, 10.1016/0021-9150(96)05809-1

Wilcken, 1988, Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease, Metabolism, 37, 697, 10.1016/0026-0495(88)90093-5

Bostom, 1996, High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients, Kidney Int, 49, 147, 10.1038/ki.1996.19

Frosst, 1995, A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase, Nature Genet, 10, 111, 10.1038/ng0595-111

Molloy, 1997, Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations, Lancet, 349, 1591, 10.1016/S0140-6736(96)12049-3

Kluijtmans, 1996, Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease, Am J Hum Genet, 58, 35

Födinger, 1997, Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients, Kidney Int, 52, 517, 10.1038/ki.1997.362

Vychytil, 1998, Major determinants of hyperhomocysteinemia in peritoneal dialysis patients, Kidney Int, 53, 1775, 10.1046/j.1523-1755.1998.00918.x

Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580

Wilcken, 1981, Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism, Clin Sci, 61, 743, 10.1042/cs0610743

Arnadottir, 1996, Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients, Transplantation, 61, 509, 10.1097/00007890-199602150-00034

Massy, 1994, Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients, Nephrol Dial Transplant, 9, 1103, 10.1093/ndt/9.8.1103

Arnadottir, 1997, Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients (letter), Transplant, 64, 1087, 10.1097/00007890-199710150-00026

Bostom, 1997, Treatment of hyperhomocysteinemia in renal transplant recipients: A randomized, placebo-controlled trial, Ann Int Med, 127, 1089, 10.7326/0003-4819-127-12-199712150-00006